- Home
- NEWT vs DMAC Comparison
NEWT vs DMAC Comparison
Compare NEWT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- DMAC
- Stock Information
- Founded
- NEWT 1998
- DMAC 2000
- Country
- NEWT United States
- DMAC United States
- Employees
- NEWT N/A
- DMAC N/A
- Industry
- NEWT Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- DMAC Health Care
- Exchange
- NEWT Nasdaq
- DMAC Nasdaq
- Market Cap
- NEWT 294.8M
- DMAC 310.1M
- IPO Year
- NEWT N/A
- DMAC N/A
- Fundamental
- Price
- NEWT $11.85
- DMAC $6.97
- Analyst Decision
- NEWT Hold
- DMAC Strong Buy
- Analyst Count
- NEWT 4
- DMAC 3
- Target Price
- NEWT $13.00
- DMAC $12.33
- AVG Volume (30 Days)
- NEWT 162.2K
- DMAC 443.2K
- Earning Date
- NEWT 11-05-2025
- DMAC 11-12-2025
- Dividend Yield
- NEWT 6.42%
- DMAC N/A
- EPS Growth
- NEWT 21.23
- DMAC N/A
- EPS
- NEWT 2.01
- DMAC N/A
- Revenue
- NEWT $364,004,000.00
- DMAC N/A
- Revenue This Year
- NEWT N/A
- DMAC N/A
- Revenue Next Year
- NEWT $12.73
- DMAC N/A
- P/E Ratio
- NEWT $5.88
- DMAC N/A
- Revenue Growth
- NEWT 20.91
- DMAC N/A
- 52 Week Low
- NEWT $9.12
- DMAC $3.19
- 52 Week High
- NEWT $15.49
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- NEWT 51.63
- DMAC 66.23
- Support Level
- NEWT N/A
- DMAC $6.83
- Resistance Level
- NEWT $11.77
- DMAC $7.41
- Average True Range (ATR)
- NEWT 0.25
- DMAC 0.42
- MACD
- NEWT -0.50
- DMAC 0.06
- Stochastic Oscillator
- NEWT 94.95
- DMAC 77.88
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.